Profile
Jeffrey R.
Latts is an Independent Director at Allos Therapeutics, Inc. since 2007.
Previously, he served as the Chief Medical Officer at Berlex, Inc. from 1990 to 2001.
He then worked as the Executive Vice President at Exelixis, Inc. from 2001 to 2007.
Additionally, he has held positions as the Chief Medical Advisor at Virobay, Inc. and as the Vice President-Clinical Research at Wyeth-Ayerst Research.
Dr. Latts completed his undergraduate and doctorate degrees at the University of Minnesota.
Jeffrey R. Latts active positions
| Companies | Position | Start |
|---|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets anti-cancer therapeutics | Director/Board Member | 25/04/2007 |
Former positions of Jeffrey R. Latts
| Companies | Position | End |
|---|---|---|
| EXELIXIS, INC. | Corporate Officer/Principal | 12/01/2007 |
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Manufactured pharmaceutical products | Chief Tech/Sci/R&D Officer | 01/01/2001 |
Virobay, Inc.
Virobay, Inc. Pharmaceuticals: MajorHealth Technology Develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases | Corporate Officer/Principal | - |
Wyeth-Ayerst Research | Chief Tech/Sci/R&D Officer | - |
Training of Jeffrey R. Latts
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Manufactured pharmaceutical products | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets anti-cancer therapeutics | Health Technology |
Exelixis, Inc.
Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Virobay, Inc.
Virobay, Inc. Pharmaceuticals: MajorHealth Technology Develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases | Health Technology |
University of Minnesota
University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wyeth-Ayerst Research |
- Stock Market
- Insiders
- Jeffrey R. Latts
















